Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
02 Jul 2024
Historique:
accepted: 19 06 2024
revised: 13 06 2024
received: 01 05 2023
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

The efficiency and outcome of CRISPR/Cas9 editing depends on the chromatin state at the cut site. It has been shown that changing the chromatin state can influence both the efficiency and repair outcome, and epigenetic drugs have been used to improve Cas9 editing. However, because the target proteins of these drugs are not homogeneously distributed across the genome, the efficacy of these drugs may be expected to vary from locus to locus. Here, we systematically analyzed this chromatin context-dependency for 160 epigenetic drugs. We used a human cell line with 19 stably integrated reporters to induce a double-stranded break in different chromatin environments. We then measured Cas9 editing efficiency and repair pathway usage by sequencing the mutational signatures. We identified 58 drugs that modulate Cas9 editing efficiency and/or repair outcome dependent on the local chromatin environment. For example, we find a subset of histone deacetylase inhibitors that improve Cas9 editing efficiency throughout all types of heterochromatin (e.g. PCI-24781), while others were only effective in euchromatin and H3K27me3-marked regions (e.g. apicidin). In summary, this study reveals that most epigenetic drugs alter CRISPR editing in a chromatin-dependent manner, and provides a resource to improve Cas9 editing more selectively at the desired location.

Identifiants

pubmed: 38953163
pii: 7702503
doi: 10.1093/nar/gkae570
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : ZonMW TOP
ID : 91 215 067
Organisme : European Research Council
ID : 694466
Pays : International
Organisme : The Dutch Cancer Society
Organisme : EU/MUR MSCA Young Researcher Fellowship

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

Auteurs

Ruben Schep (R)

Oncode Institute, The Netherlands.
Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.

Max Trauernicht (M)

Oncode Institute, The Netherlands.
Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.

Xabier Vergara (X)

Oncode Institute, The Netherlands.
Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.
Division of Cell Biology, 1066 CX Amsterdam, The Netherlands.

Anoek Friskes (A)

Oncode Institute, The Netherlands.
Division of Cell Biology, 1066 CX Amsterdam, The Netherlands.

Ben Morris (B)

Division of Molecular Carcinogenesis, 1066 CX Amsterdam, The Netherlands.

Sebastian Gregoricchio (S)

Oncode Institute, The Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Stefano G Manzo (SG)

Oncode Institute, The Netherlands.
Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.

Wilbert Zwart (W)

Oncode Institute, The Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

Roderick L Beijersbergen (RL)

Division of Molecular Carcinogenesis, 1066 CX Amsterdam, The Netherlands.

René H Medema (RH)

Oncode Institute, The Netherlands.
Division of Cell Biology, 1066 CX Amsterdam, The Netherlands.

Bas van Steensel (BV)

Oncode Institute, The Netherlands.
Division of Molecular Genetics, 1066 CX Amsterdam, The Netherlands.

Classifications MeSH